𝔖 Bobbio Scriptorium
✦   LIBER   ✦

HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia

✍ Scribed by Norah J. Shire; Paul S. Horn; Susan D. Rouster; Sandra Stanford; M. Elaine Eyster; Kenneth E. Sherman; Multicenter Hemophilia Cohort HCV Study Group


Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
691 KB
Volume
44
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

✦ Synopsis


Hepatitis C virus (HCV) treatment response rates remain low in HCV/HIV-1-coinfected individuals compared with those with HCV alone. Persons with inherited coagulation disorders have high rates of HCV and HIV-1 infection, but HCV treatment trials in this patient population are scarce. We hypothesized that differences by infection status in HCV viral kinetics would be associated with differences in HCV quasispecies complexity over time and with treatment response disparities. Coinfected and monoinfected patients were enrolled in a treatment trial for pegylated-interferon alpha-2a (peg-IFN) + ribavirin. Patients were treated for 48 weeks and followed for an additional 24. Quantitative HCV RNA was tested at multiple times during and after treatment. Viral kinetic parameters associated with response were estimated with a mathematical model. Quasispecies emergence was determined via heteroduplex complexity assay. Twenty-two patients were HCV RNA-positive at baseline, with no significant demographic or virological differences by infection status. Five of eleven (45%) of monoinfected and 3 of 11 (27%) of coinfected patients achieved sustained viral response (SVR). Peg-IFN efficacy (epsilon) of 90% or greater was associated with probability of end-of-treatment response (ETR) (P = .001) and SVR (P = .06). Patients with SVR had lower baseline quasispecies complexity than those without SVR (P = .07). Those with epsilon of 90% or greater also had lower baseline complexity (P = .07). Coinfection status mediated changes in complexity over time (P = .04). In conclusion, low pretreatment quasispecies complexity may predict peg-IFN response; early peg-IFN response is critical for sustained HCV clearance and is altered in coinfection. Further studies are warranted.


📜 SIMILAR VOLUMES


Intrahepatic HCV RNA loads in 37 HIV-HCV
✍ P. Trimoulet; D. Neau; B. Le Bail; A. Rullier; M. Winnock; T. Galperine; E. Legr 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 1 views

## Abstract Serum and intrahepatic hepatitis C virus (HCV) RNA were measured in 37 HIV‐HCV co‐infected patients with controlled human immunodeficiency virus (HIV) infection and correlated with clinical, biological, and histological parameters. Thirty‐seven interferon‐naive patients underwent liver

IL28B alleles associated with poor hepat
✍ Pierre-Yves Bochud; Stéphanie Bibert; Zoltán Kutalik; Etienne Patin; Julien Guer 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 375 KB 👁 2 views

Poynard owns stock in Biopredictive. He also consults for and is on the speakers' bureau of Merck. Dr. Pol consults for, advises, and is on the speakers' bureau of Boehringer Ingleheim, Abbott, and GlaxoSmithKline. He consults for, advises, is on the speakers' bureau of, and received grants from Roc

Serum concentrations of ribavirin and pe
✍ Florence Nicot; Florence Legrand-Abravanel; Thierry Lafont; Martine Dubois; Kari 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 1 views

## Abstract The hepatitis C virus (HCV) infects a substantial proportion of patients infected with human immunodeficiency virus (HIV). Patients infected with both HCV and HIV respond poorly to anti‐HCV treatment with pegylated interferon alpha and ribavirin. But few data are available on the influe

IP-10 predicts viral response and therap
✍ Martin Lagging; Ana I. Romero; Johan Westin; Gunnar Norkrans; Amar P. Dhillon; J 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 540 KB

Plasma from 173 patients with HCV genotype 1 infection was analyzed for IP-10 levels prior to treatment with pegylated interferon-␣-2a and ribavirin. Significantly lower IP-10 levels were observed in patients achieving a rapid viral response (RVR) (P < .0001), even in those with body mass index (BMI

Prevalence of antibody to hepatitis C vi
✍ J. F. Quaranta; S. R. Delaney; S. Alleman; J. P. Cassuto; P. Dellamonica; J. P. 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 464 KB 👁 2 views

## Abstract The prevalence of antibody to hepatitis C virus (HCV) in a cohort of 272 HIV‐infected patients was assessed by means of 4 anti‐HCV assays: a 1st generation and a neutralization test, a 2nd generation test, and a confirmatory test, the dot‐blot Matrix HCV™ immunoassay. The cohort include